More than 90% of Americans believe that the cost burden of cancer is too high, according to a large, nationally representative survey conducted for the American Society of Clinical Oncology (ASCO).
More than 90% of Americans believe that the cost burden of cancer is too high, according to a large, nationally representative survey conducted for the American Society of Clinical Oncology (ASCO). High treatment costs are compromising cancer care, the survey’s responses suggest, with more than a quarter of respondents saying that either they or an immediate family member with cancer have taken actions to reduce treatment costs that could have a negative impact on their treatment:
If diagnosed in the future, 35% of those surveyed lacked confidence that they would receive timely, best-in-class cancer care, largely because they felt they could not afford it. Among those who are undergoing treatment or have a loved one doing so, more than 44% are concerned about mounting costs. Of those paying for a family member’s cancer treatment, 68% are concerned about being able to afford it.
Concerns about cancer are greatest among Americans with experience of a loved one who has had cancer: 60% of these respondents say that they are worried about being a burden on family and friends if they personally are diagnosed, compared with 49% of those with no experience with cancer.
A large majority of Americans believe the federal government should act to lower prescription drug costs: 92% said Medicare should be allowed to directly negotiate prescription drug prices with drug makers, 86% said the US government should regulate the price of cancer drugs, and 80% said it should be legal for US residents to buy cancer drugs from other countries. Ninety-one percent believe that the federal government should dedicate substantial funding to diagnose, prevent, and treat cancer, and 73% support greater federal investment in cancer research, even if doing so means higher taxes or adding to the deficit.
The survey also revealed a lack of awareness about cancer risks. Although a majority of Americans correctly identified tobacco use (78%) and sun exposure (66%) as risk factors for cancer, far fewer are aware of other lifestyle factors that increase their cancer risk, notably, obesity; just 31% realize that obesity is a risk factor for cancer despite obesity’s current ranking as the second leading preventable cause of cancer. Fewer than a third of those surveyed recognize alcohol as a risk factor for cancer, and 80% are unaware that viruses can exacerbate the risk of certain cancers.
The National Cancer Opinion Survey was conducted online by Harris Poll for ASCO from July 10 to 18, 2017, among 4016 nationally representative US adults ages 18 and older. Among those surveyed, 1508 had been diagnosed with cancer themselves or had a loved one who had been diagnosed with cancer.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.